GeneNews To Present At AdvaMed 2012
TORONTO, Sept. 28, 2012 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN), a company focused on the development and commercialization of novel blood-based tests for the early detection of diseases and personalized health management, announced today that its President and Chief Operating Officer, Gailina J. Liew, will present an update on the Company's business at the Advanced Medical Technology Association ("AdvaMed") 2012 MedTech Conference on Tuesday, October 2 at 9:45 a.m. Eastern Time. The conference will be held at the Boston Convention & Exhibition Center.
AdvaMed 2012 is a premier event for business leaders, policy-makers, investors, media and other medical technology industry stakeholders from around the world.
About GeneNewsGeneNews is a molecular diagnostics company focused on the application of blood-based RNA molecular signatures to enable early diagnosis and personalized health management. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage a range of diseases or medical conditions from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' lead product, ColonSentry®, is the world's first blood test to pre-screen and assess an individual's current risk for colorectal cancer. For more information on GeneNews and ColonSentry®, go to www.GeneNews.com and www.ColonSentry.com . Forward-Looking Statements This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
CONTACT: Company Contact: Gailina Liew President & COO, Office: (905) 739-2036 email@example.com Investor Contact: Stephen Kilmer Kilmer Lucas Inc. Office: (212) 618-6347 firstname.lastname@example.org Media Contact: Leonard Zehr Kilmer Lucas Inc. Office: (416) 833-9317 email@example.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV